Beaver Run Resort Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2019



For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Antibodies as Drugs: New Horizons in the Therapeutic Use of Engineered Antibodies (D2)


Organizer(s) Christian Klein, Mark S. Cragg and Germaine Fuh
April 7—11, 2019
Beaver Run Resort • Breckenridge, Colorado USA
Discounted Abstract Deadline: Dec 11, 2018
Abstract Deadline: Jan 9, 2019
Scholarship Deadline: Dec 11, 2018
Discounted Registration Deadline: Feb 6, 2019

Sponsored by AbbVie Inc., Bioverativ Therapeutics, ImmunoGen, Inc., Incyte Corporation, Merck & Co., Inc., MorphoSys AG and Roche

Summary of Meeting:
Over the last 20 years, recombinant antibodies have been established into clinical practice for the treatment of diseases ranging from cancer, to autoimmune and infectious diseases. While the first approved antibodies were native IgG antibodies, in recent years the field has rapidly advanced and therapeutic antibodies in preclinical and clinical development now include many non-canonical formats including Fc- engineered antibodies, antibody drug conjugates, bispecific antibodies and antibody-like scaffolds. This Keystone Symposia conference aims to bring together experts in antibody therapeutics, engineering and mechanisms of action from industry and academia to discuss and review the state-of-the-art in the field and discuss their future potential. The conference will foster cross-fertilization between different engineering technologies and scientists from different therapeutic areas. This conference can also help to initiate collaboration on the development of state-of-the-art antibody therapies with the aim to improve therapeutic options for patients. For trainees and early career researchers, this conference provides an opportunity to gain insight into various aspects of therapeutic antibodies and to discuss their projects and ideas face-to-face with experts in the field. A unique component to this conference that distinguishes it from other more commercial meetings in the field, is that this conference will include presentation and discussion of novel/unpublished data.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 24 hr (international) time


The meeting will begin on Sunday, April 7 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, April 11 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Friday, April 12 in order to fully experience the meeting.

SUNDAY, APRIL 7

4:00—8:00 PM
Arrival and Registration

Colorado Ballroom Foyer
6:00—8:00 PM
Welcome Mixer
No registration fees are used to fund alcohol served at this function.

Colorado Ballroom Foyer

MONDAY, APRIL 8

7:00—8:00 AM
Breakfast

Summit Gallery
8:00—9:30 AM
Welcome and Keynote Session
Meeting has ended...abstracts no longer viewable online.

Colorado Ballroom
* Christian Klein, Roche, Switzerland

George D. Yancopoulos, Regeneron Pharmaceuticals, Inc., USA
Target Identification and Developing Antibodies for Clinical Application

Jennifer R. Cochran, Stanford University, USA
Emerging Strategies for Developing Next-Generation Protein Therapeutics

Coffee Break

9:50—11:45 AM
Mechanisms of Action for Depleting Antibodies
Meeting has ended...abstracts no longer viewable online.

Colorado Ballroom
* Janine Schuurman, Genmab B.V., Netherlands

Mark S. Cragg, University of Southampton, UK
Targeting B Cells with Antibodies: From Oncology to Autoimmunity

Falk Nimmerjahn, Universitätsklinikum Erlangen, Germany
The Where, When, and How: Organ Specific Pathways of Cytotoxic IgG Activity

Annalee W. Nguyen, University of Texas at Austin, USA
Short Talk: Antibodies Engineered for Enhanced Binding and Effector Activity in the Low pH of the Tumor Microenvironment

Polina Weitzenfeld, Rockefeller University, USA
Short Talk: Antibody Targeting of Carbohydrate-Associated Tumor Antigens Reveals Novel Effector Cell Pathways for Tumor Clearance

Michael Schmidt, Compass Therapeutics, USA
Short Talk: Novel Class of NK Engagers Targeting NKp30 Selected from Unbiased Screen of Common Light Chain-Based Bispecific Antibodies

11:45 AM—5:00 PM
On Own for Lunch

11:45 AM—1:00 PM
Poster Setup

Breckenridge Ballroom
1:00—10:00 PM
Poster Viewing

Breckenridge Ballroom
2:30—4:30 PM
Workshop 1: Engineering (Bispecific) Antibodies

Colorado Ballroom
* Christian Klein, Roche, Switzerland

Starlynn Clarke, TeneoBio Inc., USA
A Novel CD3xPSMA Bispecific Antibody for Efficient T-Cell Mediated Killing of Prostate Tumor Cells with Minimal Cytokine Release

Lynn A. Kamen, Genentech, Inc., USA
A Novel Cell-Based Assay for Predicting Bispecific Antibody Activity and its PK-PD Effects

Jason Lajoie, Compass Therapeutics, USA
A Versatile Platform for Efficient Affinity Optimization of Common Light Chain Bispecific Antibodies

Ahlam Qerqez, University of Texas at Austin, USA
Human Cytomegalovirus-Specific T Cell Receptor Engineered for High Affinity and Soluble Expression using Mammalian Cell Display

Diana Darowski, Roche Gylcart AG, Switzerland
Antibodies as Drugs: P329G LALA Mutated Antibodies Enable Precise Redirection of Anti-P329G-Based Chimeric Antigen Receptor T Cells (P329G-CAR-T cells)

Koen Wagner, AIMM Therapeutics, Netherlands
AT1413 T-Cell Engager Activity Is Determined by T-Cell Engager Format Valency

Phillip Liu, Sound Biologics, USA
Development of MabPair Technology, a Novel Platform for Producing Bifunctional Antibody Products

Brandy R. White, California State University, Fresno, USA
Humanization of a MUC16 Specific Monoclonal Antibody for the Treatment of Pancreatic Cancer

4:30—5:00 PM
Coffee Available

Colorado Ballroom Foyer
5:00—7:00 PM
Antibody Engineering
Meeting has ended...abstracts no longer viewable online.

Colorado Ballroom
* James A. Ernst, Genentech, Inc., USA

Janine Schuurman, Genmab B.V., Netherlands
Engineering Non-Classical Antibody Formats Inspired by Nature

Feng Wang, Chinese Academy of Sciences, China
A Tumor Targeted Immune Checkpoint Blocker

Germaine Fuh, 23andMe, USA
Engineering Antibody Specificity and Stability Using Deep Sequencing

Aliza Borenstein-Katz, Weizmann Institute, Israel
Short Talk: Optimization of Antibody Anti Pancreatic Cancer Marker

Chia Yin Lee, Singapore Immunology Network, Singapore
Short Talk: Engineering the Fragment Crystallizable (Fc) Region of Antibody for Dendritic Cell-Based Vaccine

7:00—8:00 PM
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Breckenridge Ballroom
7:30—10:00 PM
Poster Session 1

Breckenridge Ballroom

TUESDAY, APRIL 9

7:00—8:00 AM
Breakfast

Summit Gallery
8:00—11:15 AM
Bispecific and Engineered Antibodies for Cancer Immunotherapy
Meeting has ended...abstracts no longer viewable online.

Colorado Ballroom
* Andreas G. Plückthun, University of Zürich, Switzerland

Nai-Kong V. Cheung, Memorial Sloan-Kettering Cancer Center, USA
Cancer Immunotherapy and Radioimmunotherapy with Bispecific Antibodies

Christian Klein, Roche, Switzerland
Engineering Bispecific Antibodies for Combination Cancer Immunotherapy

Coffee Break

John R. Desjarlais, Xencor, Inc., USA
Bispecific Antibodies for T Cell Recruitment and T Cell Activation

Yvonne Y. Chen, University of California, Los Angeles, USA
Engineering Next-Generation Chimeric Antigen Receptors

Udaya S Rangaswamy, Teneobio, USA
Short Talk: A Novel T-Cell Bispecific Antibody Platform for Efficient T Cell-Mediated Killing of Tumor Cells with Minimal Cytokine Release

Lina Bartels, AIMM Therapeutics & Amsterdam University Medical Center, Netherlands
Short Talk: A T-Cell Engager Based on a Unique AML Patient-Derived Anti-CD43 Antibody Has a Strong Anti-AML Activity in vivo without Affecting Normal Hematopoietic Cells

Chad May, Maverick Therapeutics, USA
Short Talk: COBRA: A Novel Conditionally Active Bispecific Antibody that Regresses Established Solid Tumors in Mice

11:15 AM—5:00 PM
On Own for Lunch

11:15 AM—1:00 PM
Poster Setup

Breckenridge Ballroom
1:00—10:00 PM
Poster Viewing

Breckenridge Ballroom
4:30—5:00 PM
Coffee Available

Colorado Ballroom Foyer
5:00—7:00 PM
Antibodies for Infectious Diseases
Meeting has ended...abstracts no longer viewable online.

Colorado Ballroom
* Christoph Rader, The Scripps Research Institute, USA

David D. Ho, Aaron Diamond AIDS Research Center, USA
A Bispecific Antibody, 10E8.4/iMab, for HIV Therapy and Prevention

JoAnn A. Suzich, AstraZeneca, USA
Antibodies for the Prevention and Treatment of Viral Infections

Kartik Chandran, Albert Einstein College of Medicine, USA
Development of Engineered and Natural Antibodies as Anti-Ebola Therapeutics

Sisi Shan, Tsinghua University, China
Short Talk: Broad and Potent Bispecific Neutralizing Antibodies against Filovirus

Anna Zumsteg, Regeneron Pharmaceuticals, USA
Short Talk: Staphylococcus Aureus Specific Monoclonal Antibodies that Escape Binding to Protein A Protect against Invasive Disease

7:00—8:00 PM
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Breckenridge Ballroom
7:30—10:00 PM
Poster Session 2

Breckenridge Ballroom

WEDNESDAY, APRIL 10

7:00—8:00 AM
Breakfast

Summit Gallery
8:00—11:15 AM
Antibody Drug Conjugates
Meeting has ended...abstracts no longer viewable online.

Colorado Ballroom
* Germaine Fuh, 23andMe, USA

Ronit Mazor, MedImmune, USA
Immunogenicity of Recombinant Immunotoxins and Approaches to Mitigate It

Kerry Culm-Merdek, ImmunoGen, USA
Optimizing the Activity of Antibody Drug Conjugates

Coffee Break

John M. Lambert, , USA
Site-Specific Conjugation in ADC Design: Panacea or Hype? Lessons from a Case Study with a Maytansinoid Conjugate

W. Michael Kavanaugh, Cytomx Therapeutics, USA
Probody Therapeutics: Antibody Pro-drugs Designed for Safer and More Effective Cancer Therapies

Armine Matevossian, Novartis Institutes for BioMedical Research, USA
Short Talk: Comprehensive Profiling of the Immune-Modulatory Properties of a Cytotoxic ADC Reveals Unique Contributions by the Antibody Component of the Drug

Bradley Pearse, Magenta Therapeutics, USA
Short Talk: Antibody Drug Conjugates as Targeted Conditioning Agents for Bone Marrow Transplant Patients

Brian H. Santich, Memorial Sloan Kettering Cancer Center, USA
Short Talk: Self-Assembling and Disssembling (SADA) Bispecific Antibodies (BsAb) for 2-Step Pretargeted RadioImmunotherapy (PRIT)

11:15 AM—5:00 PM
On Own for Lunch

4:30—5:00 PM
Coffee Available

Colorado Ballroom Foyer
5:00—7:00 PM
Delivering Antibodies into the Brain
Meeting has ended...abstracts no longer viewable online.

Colorado Ballroom
* Jennifer R. Cochran, Stanford University, USA

Joy Yu Zuchero, Denali Therapeutics Inc, USA
CNS Delivery of Therapeutic Proteins using a Novel Fc Fragment Blood-Brain Barrier Transport Vehicle Approach

Per-Ola Freskgard, Roche Innovation Center Basel, Switzerland
Crossing the Blood-Brain Barrier with Antibodies to Access Brain Targets

Allan Jensen, Lundbeck, Denmark
Antibody-Based Therapies for Neurodegenerative Diseases

Mathieu Oosterlaken, Institut de Génomique Fonctionelle, France
Short Talk: Engineering Pharmacology Active Nanobodies to Target mGlu2 Receptor in the Brain

Chiara Figazzolo, University of Cambridge, UK
Short Talk: Rational Design and Systematic Optimization of Antibodies against the Aggregation of the Aβ42 Peptide

7:00—8:00 PM
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Breckenridge Ballroom

THURSDAY, APRIL 11

7:00—8:00 AM
Breakfast

Summit Gallery
8:00—11:00 AM
Bispecific Antibodies and Antibody Like Molecules
Meeting has ended...abstracts no longer viewable online.

Colorado Ballroom
* Christian Klein, Roche, Switzerland

Christoph Rader, The Scripps Research Institute, USA
Chemically Programmed Bispecific Antibodies

James A. Ernst, Genentech, Inc., USA
A Bispecific Antibody Mimetic of FGF21 for the Treatment of Metabolic Disease and NASH

Coffee Break

Andreas G. Plückthun, University of Zürich, Switzerland
Engineering DARPins for Delivery into Cells

Krzysztof Masternak, NovImmune SA, Switzerland
Bispecific CD47 Antibodies for Treatment of Cancer

Peter J. Hudson, Avipep Pty Ltd, Australia
Short Talk: Engineered Antibody Fragments Precisely Loaded with Diagnostic and Therapeutic Payloads with First-in-Man Biodistribution in Cancer Metastases

Leandrew A. Dailey, Albert Einstein College of Medicine, USA
Short Talk: Engineering Next-Generation Bispecific Antibodies against Filoviruses

11:00 AM—5:00 PM
On Own for Lunch

2:30—4:30 PM
Workshop 2: Antibodies for Immunological Applications

Colorado Ballroom
* Mark S. Cragg, University of Southampton, UK

Nicole Piché-Nicholas, Pfizer, USA
Changes in Complementarity-Determining Regions Significantly Alter IgG Binding to the Neonatal Fc Receptor (FcRn) and Pharmacokinetics

Trevor RF Smith, Inovio Pharmaceuticals, USA
Active Immunoprophylaxis Employing DNA-Encoded Monoclonal Antibodies (dMAbs™)

Olivia Vergnolle, Albert Einstein College of Medicine, USA
Dengue Virus Glycoprotein E DIII Epitope Engineering for Broadly Neutralizing Antibodies Enhancement

Masahiro Yasunaga, National Cancer Center, Japan
Development of Next-Generation Antibody Therapeutics against Cancer and Autoimmune Disease Utilizing DDS and Molecular Imaging

Henry Wilson, The Scripps Research Institute, USA
A Sortase A Programmable Phage Display Format for Improved Panning of Fab Antibody Libraries

Gregory Mann, École Polytechnique Fédérale de Lausanne, Switzerland
Using Monobodies to Target Cytoplasmic Oncoproteins

4:30—5:00 PM
Coffee Available

Colorado Ballroom Foyer
5:00—6:45 PM
Beyond Checkpoint Blockade: Novel Approaches for Immunotherapy
Meeting has ended...abstracts no longer viewable online.

Colorado Ballroom
* Mark S. Cragg, University of Southampton, UK

Mikael C. I. Karlsson, Karolinska Institutet, Sweden
Anti-Marco Antibodies in Tumor Immunotherapy

Sean Hua Lim, University of Southampton, UK
Optimizing Anti-Tumor Immunity through Manipulation of the Innate-Adaptive Interface using CD27 Agonists

Sapna Yadavilli, GlaxoSmithKline, USA
GSK 3359609 a Non-T Cell Depleting IgG4 Anti-ICOS Antibody

Wen Jie Chin, Agency for Science, Technology and Research, Singapore
Short Talk: Engineering Antibodies to Engage TRIM21 Improves Antigen Cross-Presentation in Human Monocyte-Derived Dendritic Cells

6:45—7:00 PM
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
Meeting has ended...abstracts no longer viewable online.

Colorado Ballroom
7:00—8:00 PM
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Breckenridge Ballroom
8:00—11:00 PM
Entertainment
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.

Breckenridge Ballroom

FRIDAY, APRIL 12

 
Departure


*Session Chair †Invited, not yet responded.



We gratefully acknowledge support for this conference from:


Directors' Fund


These generous unrestricted gifts allow our Directors to schedule meetings in a wide variety of important areas, many of which are in the early stages of research.

Click here to view all of the donors who support the Directors' Fund.



Keystone Symposia thanks our Sponsors for generously supporting this meeting:

AbbVie Inc. Bioverativ Therapeutics
ImmunoGen, Inc. Incyte Corporation
Merck & Co., Inc. MorphoSys AG
Roche
 

We gratefully acknowledge the generous grant for this conference provided by:


National Institutes of Health

Grant No. 1R13AI145248-01

Funding for this conference was made possible (in part) by 1R13AI145248-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.


We gratefully acknowledge additional support for this conference from:

American Association for Cancer Research (AACR) American Society of Gene & Cell Therapy (ASGCT)

We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:



CytomX Therapeutics, Inc.


Denali Therapeutics Inc.


Genmab B.V.


ImmunoGen, Inc.


Lundbeck


NovImmune SA


Regeneron Pharmaceuticals, Inc.


Roche


Xencor, Inc.


We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Nick Dua, Senior Director, Communications, Email: nickd@keystonesymposia.org,
Phone:+1 970-262-1179